PRTA
Prothena·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PRTA Profile
Prothena Corporation Plc
A late-stage clinical biotechnology company that develops therapeutics for AL and AA forms of amyloidosis, Parkinson's disease and inflammatory diseases
Biological Technology
09/26/2012
12/21/2012
NASDAQ Stock Exchange
163
12-31
Common stock
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland
--
Prothena Corporation plc was incorporated under the laws of Ireland on 26 September 2012 and re-registered as an Irish public limited company on 25 October 2012. The company is a late-stage clinical biotechnology company with expertise in protein disorders and a range of investigational therapies that have the potential to alter the course of disruptive neurodegenerative diseases and rare peripheral amyloid diseases. The company's wholly-owned projects include birtamimab for the potential treatment of AL amyloidosis, and a series of projects for the potential treatment of Alzheimer's disease, including PRX012 for β-amyloid (Aβ) and the new Aβ-tau dual vaccine PRX123.
